CRISPR Therapeutics (CRSP) vs. The Competition Financial Survey

CRISPR Therapeutics (NASDAQ:CRSP) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare CRISPR Therapeutics to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.

Valuation & Earnings

This table compares CRISPR Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CRISPR Therapeutics	$3.51 million	-$581.60 million	-8.91
CRISPR Therapeutics Competitors	$702.34 million	$9.48 million	-18.76

CRISPR Therapeutics’ competitors have higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

CRISPR Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics’ competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Insider and Institutional Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CRISPR Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1	6	8	2	2.65
CRISPR Therapeutics Competitors	9874	15294	45655	1600	2.54

CRISPR Therapeutics currently has a consensus target price of $72.93, suggesting a potential upside of 72.67%. As a group, “Biotechnology” companies have a potential upside of 126.23%. Given CRISPR Therapeutics’ competitors higher probable upside, analysts plainly believe CRISPR Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares CRISPR Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
CRISPR Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Summary

CRISPR Therapeutics beats its competitors on 8 of the 13 factors compared.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.